Skip to content
healthcare.dev

VIMIZIM

NDC 68135-100, elosulfase alfa, injection, solution, concentrate, from BioMarin Pharmaceutical Inc..

Product NDC
68135-100
Status
Listed
Labeler
BioMarin Pharmaceutical Inc.
Dosage form
INJECTION, SOLUTION, CONCENTRATE
Route
INTRAVENOUS
Product type
HUMAN PRESCRIPTION DRUG
Marketing category
BLA
Application
BLA125460
DEA schedule
None
Request
curl https://api.healthcare.dev/v1/drugs/ndc/68135-100 \
  -H "Authorization: Bearer $HDEV_API_KEY"

Product

Active ingredients and packages

Active ingredients

  • ELOSULFASE ALFA5 mg/5mL

Pharmacologic classes

Hydrolytic Lysosomal Glycosaminoglycan-specific Enzyme [EPC]; alpha-Glucosidases [CS]

Package NDCNDC-11Package
68135-100-01681350100011 VIAL in 1 CARTON (68135-100-01) / 5 mL in 1 VIAL

Linked data

RxNorm, label and prices

RxNorm concepts

Related lookups

  • FDA label sections

    GET /v1/drugs/labels/0caa2565-12b2-0ad0-1f9a-273e81c3d4cc
  • Medicare Part B payment limits (ASP)

    GET /v1/drugs/asp?ndc=68135-100

Use it

Look up 68135-100 from code or an agent

curl
curl https://api.healthcare.dev/v1/drugs/ndc/68135-100 \
  -H "Authorization: Bearer $HDEV_API_KEY"
MCP prompt
Using the healthcare.dev MCP server, look up NDC 68135-100. Tell me the product, its labeler, dosage form and route, its packages, and the RxNorm concepts it maps to.

Source: FDA, release 2026-10-23. Public domain. Reference data, not medical advice.